KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Account Payables (2020 - 2026)

Aquestive Therapeutics has reported Change in Account Payables over the past 6 years, most recently at $19.2 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 630.16% year-over-year to $19.2 million; the TTM value through Dec 2025 reached $19.5 million, up 601.76%, while the annual FY2025 figure was $19.5 million, 601.76% up from the prior year.
  • Change in Account Payables for Q4 2025 was $19.2 million at Aquestive Therapeutics, up from -$1.3 million in the prior quarter.
  • Over five years, Change in Account Payables peaked at $19.2 million in Q4 2025 and troughed at -$3.0 million in Q2 2024.
  • A 5-year average of $1.2 million and a median of $287000.0 in 2022 define the central range for Change in Account Payables.
  • Biggest five-year swings in Change in Account Payables: tumbled 1047.24% in 2021 and later soared 1270.33% in 2023.
  • Year by year, Change in Account Payables stood at $2.1 million in 2021, then plummeted by 153.6% to -$1.1 million in 2022, then rose by 5.07% to -$1.1 million in 2023, then skyrocketed by 346.82% to $2.6 million in 2024, then soared by 630.16% to $19.2 million in 2025.
  • Business Quant data shows Change in Account Payables for AQST at $19.2 million in Q4 2025, -$1.3 million in Q3 2025, and -$323000.0 in Q2 2025.